IMNM
Immunome, Inc.$22.76+0.17 (+0.75%)Prev Close$22.59·MCap$2.23B·P/E—·Vol464.6K·Yield—
▲
Buys (12M)
8
$2.31M
▼
Sells (12M)
11
$21.76M
◆
Net Activity
Net Seller
$19.46M
●
Active Insiders
10
last 12 mo
Over the past 12 months, insider activity at Immunome, Inc. (IMNM) has been dominated by selling, with 8 insider purchases totaling $2.31M and 11 insider sales totaling $21.76M. The most recent insider transaction was by Horn Kinney (officer: CHIEF BUSINESS OFFICER), who sold $27.3K worth of shares on Jul 9, 2026. Immunome, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.23B.
IMNM Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Horn Kinney | officer: CHIEF BUSINESS OFFICER | Sell | 1,092 | $25.00 | $27.3K | 0Exit |
| Jul 7, 2026 | Lechleider Robert | officer: Chief Medical Officer | Sell | 55,000 | $22.62 | $1.24M | 48,091-53% |
| Jul 7, 2026 | Barchas Isaac | director | Sell | 100,000 | $24.13 | $2.41M | 125,410-44% |
| Jul 2, 2026 | Barchas Isaac | director | Sell | 201,050 | $21.85 | $4.39M | 308,504-39% |
| Jun 29, 2026 | Lechleider Robert | officer: Chief Medical Officer | Sell | 55,000 | $19.85 | $1.09M | 30,225-65% |
| Jun 17, 2026 | Rosett Max | officer: Chief Financial Officer | Sell | 60,000 | $18.23 | $1.09M | 54,037-53% |
| Jun 9, 2026 | BIENAIME JEAN JACQUES | director | Buy | 10,500 | $19.45 | $204.3K | 43,415+32% |
| Jun 9, 2026 | BIENAIME JEAN JACQUES | director | Sell | 10,500 | $19.41 | $203.8K | 42,915 |
| May 19, 2026 | BIENAIME JEAN JACQUES | director | Buy | 5,000 | $20.70 | $103.5K | 43,415 |
| Apr 3, 2026 | Rosett Max | officer: Chief Financial Officer | Sell | 65,000 | $21.92 | $1.42M | 55,381-54% |
| Apr 3, 2026 | Higgins Jack | officer: Chief Scientific Officer | Sell | 9,438 | $21.64 | $204.2K | 22,000-30% |
| Mar 31, 2026 | SIEGALL CLAY B | director, officer: President and CEO | Buy | 25,450 | $19.67 | $500.6K | 690,704 |
| Mar 23, 2026 | WAGENHEIM PHILIP | director | Sell | 65,000 | $20.55 | $1.34M | 369,347 |
| Mar 12, 2026 | BIENAIME JEAN JACQUES | director | Buy | 2,000 | $21.84 | $43.7K | 38,415 |
| Dec 30, 2025 | SIEGALL CLAY B | President and CEO | Buy | 4,729 | $21.15 | $100.0K | 0 |
| Dec 22, 2025 | Barchas Isaac | Director | Sell | 383,200 | $21.74 | $8.33M | 0 |
| Dec 19, 2025 | Tsai Philip | Chief Technical Officer | Buy | 10,000 | $20.49 | $204.9K | 0 |
| Dec 19, 2025 | SIEGALL CLAY B | President and CEO | Buy | 7,278 | $20.48 | $149.1K | 0 |
| Dec 18, 2025 | SIEGALL CLAY B | President and CEO | Buy | 46,511 | $21.50 | $1000.0K | 0 |
| Jun 3, 2025 | BIENAIME JEAN JACQUES | Director | Buy | 5,000 | $9.38 | $46.9K | 0 |
| Mar 26, 2025 | SIEGALL CLAY B | President and CEO | Buy | 137,100 | $7.29 | $999.5K | 0 |
| Mar 25, 2025 | BIENAIME JEAN JACQUES | Director | Buy | 7,800 | $7.78 | $60.7K | 0 |
| Mar 24, 2025 | BIENAIME JEAN JACQUES | Director | Buy | 7,000 | $8.21 | $57.5K | 0 |
| Mar 24, 2025 | Tsai Philip | Chief Technology Officer | Buy | 12,300 | $8.42 | $103.6K | 0 |
| Feb 3, 2025 | SIEGALL CLAY B | President and CEO | Buy | 150,000 | $7.75 | $1.16M | 669,636+29% |
| Nov 25, 2024 | SIEGALL CLAY B | President and CEO | Buy | 100,000 | $9.62 | $962.2K | 519,636 |
| Nov 25, 2024 | Lechleider Robert | Chief Medical Officer | Buy | 15,805 | $9.48 | $149.8K | 15,805 |
| Nov 25, 2024 | Tsai Philip | Chief Technology Officer | Buy | 21,000 | $9.43 | $198.0K | 21,000 |
| Sep 20, 2024 | Rosett Max | Chief Financial Officer | Sell | 14,380 | $16.01 | $230.2K | 47,476 |
| Aug 19, 2024 | Higgins Jack | Chief Scientific Officer | Sell | 3,524 | $13.92 | $49.1K | 16,000 |
| Aug 19, 2024 | BIENAIME JEAN JACQUES | Buy | 7,000 | $13.94 | $97.6K | 16,615+73% | |
| May 22, 2024 | BIENAIME JEAN JACQUES | Buy | 2,000 | $13.57 | $27.1K | 9,615+26% | |
| May 21, 2024 | SIEGALL CLAY B | President and CEO | Buy | 100,000 | $13.88 | $1.39M | 419,636+31% |
| Oct 4, 2023 | SIEGALL CLAY B | President and CEO | Buy | 169,204 | $5.91 | $1000.0K | 319,636+112% |
| Oct 4, 2023 | Turner Bruce | Chief Strategy Officer | Buy | 42,300 | $5.91 | $250.0K | 42,300 |
| Sep 14, 2021 | RAPP MICHAEL | Director | Buy | 25,962 | $19.96 | $518.2K | 208,742 |
| Sep 13, 2021 | RAPP MICHAEL | Director | Buy | 45,950 | $18.07 | $830.4K | 182,780+34% |
| May 26, 2021 | WAGENHEIM PHILIP | Director | Buy | 13,500 | $18.35 | $247.7K | 397,397 |
| May 26, 2021 | RAPP MICHAEL | Director | Buy | 53,498 | $18.38 | $983.4K | 136,830+64% |
| May 26, 2021 | Lefenfeld Michael | Director | Buy | 4,650 | $18.53 | $86.1K | 26,872 |
| May 26, 2021 | Sarma Purnanand D | President and CEO | Buy | 10,500 | $18.41 | $193.3K | 10,500 |
| May 26, 2021 | LAMATTINA JOHN L | Director | Buy | 5,440 | $18.57 | $101.0K | 51,828 |
IMNM Insider Buying Activity
The following table shows recent insider purchases of Immunome, Inc. (IMNM) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | BIENAIME JEAN JACQUES | director | Buy | 10,500 | $19.45 | $204.3K | 43,415+32% |
| May 19, 2026 | BIENAIME JEAN JACQUES | director | Buy | 5,000 | $20.70 | $103.5K | 43,415 |
| Mar 31, 2026 | SIEGALL CLAY B | director, officer: President and CEO | Buy | 25,450 | $19.67 | $500.6K | 690,704 |
| Mar 12, 2026 | BIENAIME JEAN JACQUES | director | Buy | 2,000 | $21.84 | $43.7K | 38,415 |
| Dec 30, 2025 | SIEGALL CLAY B | President and CEO | Buy | 4,729 | $21.15 | $100.0K | 0 |
| Dec 19, 2025 | Tsai Philip | Chief Technical Officer | Buy | 10,000 | $20.49 | $204.9K | 0 |
| Dec 19, 2025 | SIEGALL CLAY B | President and CEO | Buy | 7,278 | $20.48 | $149.1K | 0 |
| Dec 18, 2025 | SIEGALL CLAY B | President and CEO | Buy | 46,511 | $21.50 | $1000.0K | 0 |
| Jun 3, 2025 | BIENAIME JEAN JACQUES | Director | Buy | 5,000 | $9.38 | $46.9K | 0 |
| Mar 26, 2025 | SIEGALL CLAY B | President and CEO | Buy | 137,100 | $7.29 | $999.5K | 0 |
| Mar 25, 2025 | BIENAIME JEAN JACQUES | Director | Buy | 7,800 | $7.78 | $60.7K | 0 |
| Mar 24, 2025 | BIENAIME JEAN JACQUES | Director | Buy | 7,000 | $8.21 | $57.5K | 0 |
| Mar 24, 2025 | Tsai Philip | Chief Technology Officer | Buy | 12,300 | $8.42 | $103.6K | 0 |
| Feb 3, 2025 | SIEGALL CLAY B | President and CEO | Buy | 150,000 | $7.75 | $1.16M | 669,636+29% |
| Nov 25, 2024 | SIEGALL CLAY B | President and CEO | Buy | 100,000 | $9.62 | $962.2K | 519,636 |
| Nov 25, 2024 | Lechleider Robert | Chief Medical Officer | Buy | 15,805 | $9.48 | $149.8K | 15,805 |
| Nov 25, 2024 | Tsai Philip | Chief Technology Officer | Buy | 21,000 | $9.43 | $198.0K | 21,000 |
| Aug 19, 2024 | BIENAIME JEAN JACQUES | Buy | 7,000 | $13.94 | $97.6K | 16,615+73% | |
| May 22, 2024 | BIENAIME JEAN JACQUES | Buy | 2,000 | $13.57 | $27.1K | 9,615+26% | |
| May 21, 2024 | SIEGALL CLAY B | President and CEO | Buy | 100,000 | $13.88 | $1.39M | 419,636+31% |
| Oct 4, 2023 | SIEGALL CLAY B | President and CEO | Buy | 169,204 | $5.91 | $1000.0K | 319,636+112% |
| Oct 4, 2023 | Turner Bruce | Chief Strategy Officer | Buy | 42,300 | $5.91 | $250.0K | 42,300 |
| Sep 14, 2021 | RAPP MICHAEL | Director | Buy | 25,962 | $19.96 | $518.2K | 208,742 |
| Sep 13, 2021 | RAPP MICHAEL | Director | Buy | 45,950 | $18.07 | $830.4K | 182,780+34% |
| May 26, 2021 | WAGENHEIM PHILIP | Director | Buy | 13,500 | $18.35 | $247.7K | 397,397 |
| May 26, 2021 | RAPP MICHAEL | Director | Buy | 53,498 | $18.38 | $983.4K | 136,830+64% |
| May 26, 2021 | Lefenfeld Michael | Director | Buy | 4,650 | $18.53 | $86.1K | 26,872 |
| May 26, 2021 | Sarma Purnanand D | President and CEO | Buy | 10,500 | $18.41 | $193.3K | 10,500 |
| May 26, 2021 | LAMATTINA JOHN L | Director | Buy | 5,440 | $18.57 | $101.0K | 51,828 |
IMNM Insider Selling Activity
The following table shows recent insider sales of Immunome, Inc. (IMNM) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Horn Kinney | officer: CHIEF BUSINESS OFFICER | Sell | 1,092 | $25.00 | $27.3K | 0Exit |
| Jul 7, 2026 | Lechleider Robert | officer: Chief Medical Officer | Sell | 55,000 | $22.62 | $1.24M | 48,091-53% |
| Jul 7, 2026 | Barchas Isaac | director | Sell | 100,000 | $24.13 | $2.41M | 125,410-44% |
| Jul 2, 2026 | Barchas Isaac | director | Sell | 201,050 | $21.85 | $4.39M | 308,504-39% |
| Jun 29, 2026 | Lechleider Robert | officer: Chief Medical Officer | Sell | 55,000 | $19.85 | $1.09M | 30,225-65% |
| Jun 17, 2026 | Rosett Max | officer: Chief Financial Officer | Sell | 60,000 | $18.23 | $1.09M | 54,037-53% |
| Jun 9, 2026 | BIENAIME JEAN JACQUES | director | Sell | 10,500 | $19.41 | $203.8K | 42,915 |
| Apr 3, 2026 | Rosett Max | officer: Chief Financial Officer | Sell | 65,000 | $21.92 | $1.42M | 55,381-54% |
| Apr 3, 2026 | Higgins Jack | officer: Chief Scientific Officer | Sell | 9,438 | $21.64 | $204.2K | 22,000-30% |
| Mar 23, 2026 | WAGENHEIM PHILIP | director | Sell | 65,000 | $20.55 | $1.34M | 369,347 |
| Dec 22, 2025 | Barchas Isaac | Director | Sell | 383,200 | $21.74 | $8.33M | 0 |
| Sep 20, 2024 | Rosett Max | Chief Financial Officer | Sell | 14,380 | $16.01 | $230.2K | 47,476 |
| Aug 19, 2024 | Higgins Jack | Chief Scientific Officer | Sell | 3,524 | $13.92 | $49.1K | 16,000 |
IMNM Insiders
Similar Stocks to IMNM
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B